Advanced imaging techniques for brain tumor surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on improving surgical outcomes for patients with IDH-wildtype glioblastoma and grade IV IDH-mutant astrocytoma by utilizing advanced imaging techniques. It aims to identify tumor regions with lower infiltration using a combination of apparent diffusion coefficient MRI and O-(2-[18F]fluoroethyl-)-L-tyrosine PET, which is believed to be more accurate than traditional MRI methods. The goal is to guide a more precise supramarginal resection during surgery, potentially leading to better patient prognoses. The study involves patients who are eligible for surgical resection and have visible FET PET uptake in their tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* New clinical and radiological suspected diagnosis of IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma
* Visible FET PET uptake in the tumor as assessed by the nuclear physician
* Indication for a surgical resection and adjuvant treatment according to the neuro oncology multidisciplinary meeting
* Eligible for a supramarginal resection according to two neurosurgeons in consensus
* Karnofsky Performance Score (KPS) ≥ 70.

Exclusion Criteria:

* Previous brain surgery or cranial radiotherapy
* No significant other brain pathology, in the opinion of the PI or designee, such as multiple sclerosis, neurodegenerative disease, stroke
* Tumor located infratentorially or in the spinal cord
* Lack of adequate social or family support needed for adherence to the further postoperative therapeutic regimen
* Pregnancy

Where it's running

• Amsterdam UMC location VUmc
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Study coordinator: Niels Verburg, MD PhD
• Email: n.verburg@amsterdamumc.nl
• Phone: +31204445013

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Valproic acid, irinotecan, and simvastatin for recurrent glioma in adults

  This trial tests whether the combination of valproic acid, irinotecan, and simvastatin can stabilize or shrink recurrent glioblastoma or IDH-mutant gliomas in adults.

  Recruiting Phase 2 Inova Health Care Services · Fairfax, Virginia · NCT07831369

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Lixumistat window of opportunity in newly diagnosed glioblastoma

  This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.

  Recruiting Early Phase 1 University of Miami · Miami, Florida · NCT07884344

• Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care

  A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.

  Recruiting Centre Hospitalier Universitaire de la Réunion · Saint-Pierre · NCT07865195

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.